{"entity":{"id":"shilpa-gupta","kind":"person","name":"Shilpa Gupta","aka":[],"tldr":"Genitourinary oncologist leading bladder and kidney cancer trials and national guideline work.","summary":"Shilpa Gupta is Director of Genitourinary Medical Oncology at Cleveland Clinic Taussig Cancer Institute. She is a genitourinary oncologist known for leading bladder and kidney cancer trials, as an investigator on enfortumab vedotin, immunotherapy and adjuvant renal cell carcinoma studies, and for national guideline work as co-chair of national bladder cancer committees. Her selected paper reports enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. She directs GU medical oncology at Cleveland Clinic and continues immunotherapy trials in bladder and kidney cancer.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gupta%20S%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["urothelial","rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["enfortumab-vedotin","pembrolizumab"],"companies":[],"institutions":["cleveland-clinic"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Genitourinary Medical Oncology","institutionId":"cleveland-clinic","specialisms":["Bladder cancer","Kidney cancer","Immunotherapy trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gupta%20S%5BAuthor%5D"}],"papers":[{"title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","journal":"New England Journal of Medicine","year":2024},{"title":"EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2312117","doi":"10.1056/NEJMoa2312117"}]},"route":"/people/shilpa-gupta/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"cleveland-clinic","kind":"institution","name":"Cleveland Clinic Taussig Cancer Institute","route":"/institutions/cleveland-clinic/"}],"paper":[{"id":"paper-ev-302-nejm-2024","kind":"paper","name":"EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer","route":"/key-papers/paper-ev-302-nejm-2024/"}]}}